Key Drivers
- Liquidity Strength
- Earnings Deterioration
- Manageable Leverage
AIAI Summary
BIO is no longer just a “cheap, high-quality” name—the key question is whether its strong balance sheet can offset the latest quarter's sharp earnings/EBITDA deterioration from weak academic demand, with upside only if profitability normalizes and the stock reclaims $300-$318 while holding $270 support.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Strength
- •Earnings Deterioration
- •Manageable Leverage
BIO remains financially sturdy with strong liquidity, manageable leverage, and positive free cash flow, but the latest quarter's steep drop to a large loss and negative EBITDA raises near-term earnings risk.
Price Behavior
Key Price Behavior Insights:
- •Short-term rebound
- •Overhead resistance
- •Volatile recovery
BIO's trend has softened over the last month, but the sharp rebound from $270.32 to $300.79 suggests a short-term recovery is forming as it tests resistance near $298-$300.
Sharp rebound from $270.32 to $300.79 after the selloff suggests aggressive buying
Sentiment & News
Key News Insights:
- •Conference partnering
- •AI-driven workflows
- •BIO valuation gains
BIO 2026 dominated biotech headlines as companies used the convention to push AI-driven R&D, manufacturing, and partnership plans, while Bio-Rad (BIO) drew stock gains on valuation and balance-sheet strength.
The mix of deal-making visibility and favorable stock reaction should keep BIO in focus, though regulatory-process concerns remain a modest overhang
Similar Companies in Healthcare
Other companies in the same sector with AI ratings